Huizhou First Hospital

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Stroke4 trials
• Ulcerative colitis3 trials
• Crohn's disease2 trials
• Metastatic breast cancer2 trials
• Chronic kidney disease1 trial
• Liver cirrhosis1 trial
• Lung cancer1 trial
• Neuromyelitis optica (NMOSD)1 trial

Phase

• Phase 36 trials
• Phase 24 trials
• Phase 1/22 trials
• Phase 2/32 trials
• Phase 41 trial

Status

• Recruiting7 trials
• Completed4 trials
• Active, not recruiting3 trials
• Not yet recruiting1 trial

Lead sponsor

• Beijing Tiantan Hospital2 trials
• Hoffmann-La Roche2 trials
• Shanghai Pharmaceuticals Holding Co., Ltd2 trials
• Beijing Protgen Biotechnology Development Co., Ltd.1 trial
• BioNTech SE1 trial
• and 7 more

Running trials

• Not yet recruiting

  Ongericimab Injection Reducing Recurrence of Ischemic Stroke

  NCT07242599· Phase 3· Beijing Tiantan Hospital· Source

  Contact: Chunsheng Cai

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)

  NCT07265570· Phase 2· InSilico Medicine Hong Kong Limited· Source

  Contact: Yang Deng

• Active, not recruiting

  A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment

  NCT07220538· Phase 4· Dr. Willmar Schwabe GmbH & Co. KG· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

  NCT06827236· Phase 1/2· BioNTech SE· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06589986· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

  NCT06413654· Phase 2/3· Shanghai Jiaolian Drug Research and Development Co., Ltd· Source

  Contact: Qianwu Zhou

• Recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  NCT06233461· Phase 2· Takeda· Source

  Contact: Xuanfang Zhong (principal investigator)

• Recruiting

  A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.

  NCT06064812· Phase 1/2· Forward Pharmaceuticals Co., Ltd.· Source

  Contact: Jun Li

• Active, not recruiting

  A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

  NCT05388669· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease2 recruiting
• Metastatic breast cancer2 recruiting
• Stroke2 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites

  NCT06553456· Phase 2/3· Beijing Protgen Biotechnology Development Co., Ltd.· Source

• Completed

  A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

  NCT05770609· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source

• Completed

  Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

  NCT05593575· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source

• Completed

  Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3)

  NCT05439356· Phase 3· Beijing Tiantan Hospital· Source